Ulleung county is a small island on the eastern side of the Korean peninsula. The Ulleung Liver Cancer Prevention and Management Project was launched in order to minimize newly developing liver cancer within this region. Population-based regional cancer registry data were analyzed to investigate the status and characteristics of registered liver cancer patients. The Interagency Workgroup of the project provided a special screening program from 1 November to 3 November 2018, and from 23 April to 25 April 2019, undertaking liver cancer screening and health behavior surveys. Logistic regression analysis was used to determine factors associated with recent liver cancer screening. In Ulleung county, hepatocellular carcinoma was identified as the main type of liver cancer, accompanied by a high incidence of hepatitis B. Approximately 25.0% of the participants were not aware of their liver condition. People who were aware of their liver condition and those who reported a general understanding of hepatitis B were more likely to have undergone recent liver cancer screening. To prevent the development and spread of the disease in the community, adequate infrastructure for cancer screening and an enhanced monitoring system are required, along with measures to create awareness to periodically determine liver condition in high-risk groups.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660348 | PMC |
http://dx.doi.org/10.3390/ijerph17217757 | DOI Listing |
J Nutr Educ Behav
January 2025
Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, Jiangsu, China. Electronic address:
Objective: To explore the knowledge-action gap regarding health behaviors and their influencing factors among patients with metabolic dysfunction-associated fatty liver disease (MAFLD), using the Health Belief Model as a theoretical framework.
Design: A qualitative approach was adopted, involving semistructured interviews with individuals with MAFLD.
Setting: Participants were recruited from a community hospital and a tertiary hospital in Nanjing, China, between July and October 2022.
Mol Ther
January 2025
Department of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:
Gene therapy with Adeno-Associated Virus (AAV) vectors requires knowledge of their tropism within the body. Here we analyze the tropism of ten naturally occurring AAV serotypes (AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh8, AAVrh10 and AAVrh74) following systemic delivery into male and female mice. A transgene expressing ZsGreen and Cre recombinase was used to identify transduction in a cell-dependent manner based on fluorescence.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Cell Death Dis
January 2025
Department of Organ Transplantation and Hepatobiliary Surgery, Key Laboratory of Organ Transplantation of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
TSC2, a suppressor of mTOR, is inactivated in up to 20% of HBV-associated liver cancer. This subtype of liver cancer is associated with aggressive behavior and early recurrence after hepatectomy. Being the first targeted regimen for advanced liver cancer, sorafenib has limited efficacy in HBV-positive patients.
View Article and Find Full Text PDFZhonghua Nei Ke Za Zhi
February 2025
Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou215000, China.
To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular careinoma (uHCC). The clinical data of 64 patients with unresectable HCC, who were admitted to the First Affiliated Hospital of Soochow University between January 2021 and December 2023, were retrospectively analyzed. The patients were divided into a combination group (=43, receiving TACE combined with sintilimab and bevacizumab biosimilar) and control group (=21, receiving only sintilimab and bevacizumab biosimilar).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!